CalciMedica to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Rhea-AI Summary
CalciMedica (Nasdaq: CALC), a clinical-stage biopharmaceutical company specializing in CRAC channel inhibition therapies for inflammatory and immunologic illnesses, has announced its participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference.
The company's CEO, Rachel Leheny, Ph.D., will deliver a presentation on Wednesday, February 12, 2025, at 8:00 a.m. ET. Interested parties can access a live webcast of the presentation through CalciMedica's IR website under the 'Upcoming Events' section. The presentation recording will remain available on the company's website for 90 days following the event.
Positive
- None.
Negative
- None.
A live webcast of the presentation can be accessed in the "Upcoming Events" section of CalciMedica's IR website at https://ir.calcimedica.com/. A replay of the webcast will be archived on the Company's website for 90 days.
About CalciMedica
CalciMedica is a clinical-stage biopharmaceutical company focused on developing novel CRAC channel inhibition therapies for inflammatory and immunologic diseases. CalciMedica's proprietary technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory and immunologic diseases for which there are currently no approved therapies. CalciMedica's lead product candidate Auxora™ has demonstrated positive and consistent clinical results in multiple completed efficacy clinical trials. CalciMedica has announced data for a Phase 2b trial (called CARPO – NCT04681066) in patients with acute pancreatitis (AP) and accompanying systemic inflammatory response syndrome (SIRS). The Company has also completed a Phase 2 trial (called CARDEA – NCT04345614) in patients with COVID pneumonia. The Company is currently conducting a Phase 2 trial (called KOURAGE – NCT06374797) in patients with acute kidney disease (AKI) with associated acute hypoxemic respiratory failure (AHRF) with data expected in 2025 and continuing to support the ongoing Phase 1/2 trial (called CRSPA – NCT04195347) in pediatric patients with asparaginase-induced pancreatic toxicity (AIPT) with data expected in 2025. CalciMedica was founded by scientists from Torrey Pines Therapeutics and the Harvard CBR Institute for Biomedical Research, and is headquartered in La Jolla, CA. For more information, please visit www.calcimedica.com.
Contact Information
Argot Partners
Sarah Sutton/Kevin Murphy
calcimedica@argotpartners.com
(212) 600-1902
View original content to download multimedia:https://www.prnewswire.com/news-releases/calcimedica-to-participate-in-the-oppenheimer-35th-annual-healthcare-life-sciences-conference-302366737.html
SOURCE CalciMedica, Inc.
FAQ
When is CalciMedica (CALC) presenting at the Oppenheimer Healthcare Conference 2025?
How can investors watch CalciMedica's (CALC) Oppenheimer Conference presentation?
How long will CalciMedica's (CALC) Oppenheimer Conference presentation be available for replay?
What type of therapies is CalciMedica (CALC) developing?
